Younger Generations Are Testing Biologically Older, and Early Cancer Is Tracking the Gap

In a lab at Washington University in St. Louis, Ruiyi Tian and Yin Cao set out to answer the question that has nagged oncologists for a decade: why are people too young for a cancer diagnosis getting one anyway. They lined birth cohorts up against their own blood chemistry, and the answer is easy to state and hard to shake. A body born in the 1990s is not aging the way a body born in the 1960s did. By the markers, it is running ahead of schedule.

Pulling from the UK Biobank’s records on more than 154,000 adults and roughly 10,000 more from the NIH’s All of Us program, the team estimated each person’s biological age from blood biomarkers, then compared the generations at matched chronological ages. Britons born between 1965 and 1974 carried systemic aging that ran 23 percent of a standard deviation above those born between 1950 and 1954. The American cohort born in the 1990s ran 92 percent of a standard deviation above the one born in the late 1960s. The acceleration is not gentle, and it is getting steeper with every decade of birthdays.

Greater systemic aging tracked a higher risk of early-onset solid cancer, about 8 percent per increment of aging, and 15 percent for the most biologically aged quartile measured against the least. The association was driven by lung, gastrointestinal, uterine and colorectal tumors, and it held up after the researchers adjusted for the inherited genetic risk of both aging and cancer. Advanced immune-system aging leaned toward lung cancer; advanced fat-tissue aging leaned toward the colon.

The aging gap between the generations was dramatic. The cancer signal it produced was modest.

The design is what keeps that gap honest. Biological age was read once, from a nine-marker blood panel called PhenoAge and backed by a metabolomic score and organ-specific proteomics, so the researchers were photographing bodies at a single moment, not filming them from youth to diagnosis. Nobody watched a young body age into a tumor. What the numbers show is a correlation, sturdy and adjusted for inherited risk, between how old your blood reads and how likely you are to get a cancer young. Correlation, not cause, and the paper says so.

It also lands in familiar company. The rise in cancers among the young is not a rumor and not new. Colorectal cancer in adults under 50 has been climbing for years, enough that screening was pulled down to age 45. Even the appendix, an organ most people never think about, is showing faster-rising cancer rates in younger adults. The WashU work does not discover the trend. It offers a mechanism for it, and puts a number on how much faster the clock is turning.

What the study does with that mechanism is where the reporting and the reflex part ways. Cao’s framing, repeated in the Washington University release, is prevention as personalization: “If we can identify younger people with the highest cancer risk when they are still healthy, we can focus on prevention and early-detection strategies for the individuals who will benefit most.” The ultimate goal, she says, is to “decode how modern environments become biologically embedded to drive cancer risk.”

That phrase, “modern environments,” is carrying a great deal of weight, and the study sets almost none of it down. It gestures at the usual suspects, the ultra-processed food that now anchors the Western plate, the metabolic disease arriving two decades earlier than it once did, the chemical and dietary load piled up over fifty years, and names not a single one of them. Which of those exposures is doing the embedding is my inference, not the paper’s finding; the paper identifies no specific cause at all. What it reaches for instead, twice, is the individual: find the high-risk people early and intervene on them.

Read the two halves of the finding against each other and the emphasis starts to look like a choice. A generation arriving biologically old is a population-level harm, the kind that points upstream at what people are eating, breathing, and absorbing before they turn thirty. A blood test that flags the unlucky is a product, and a screening pathway is a billing code. One of those follows the evidence toward its uncomfortable source. The other turns a story about a whole cohort aging early into a story about individuals who should get scanned sooner. The work was funded through the Cancer Grand Challenges consortium, National Cancer Institute and Cancer Research UK money on top of NIH grants and hospital-foundation support, and a research apparatus built like that is far more comfortable pricing a risk score than indicting a food supply.

Tian and Cao have documented the gap with more rigor than anyone before them, and the documentation is the achievement. Naming what pried it open, the exposures doing the biological embedding, is left to a future grant and a different set of enemies. That work tends to move slowly, for reasons that have less to do with the science than with whose products would end up in the frame.

Sources

1. Nature Medicine – Tian, Cao et al., “Biological aging and generational shifts in early-onset cancer risk” (2026)
2. News-Medical – “Accelerated biological aging may drive rising early-onset cancer risk,” WashU release with quotes and effect sizes (2026)
3. Nature Medicine – “Biological aging might help to explain the rising risk of early-onset cancer” (commentary, 2026)
4. eBioMedicine – “The colorectal cancer conundrum: the rising burden in younger adults” (2025)
5. Oncology Times – “Rates of Appendix Cancer Increasing Faster in Younger Adults” (2025)
6. ScienceDaily – “Cancer is rising in younger adults. Faster biological aging may help explain why” (2026)